FinancialGovernment SolutionsLegalReuters News AgencyRisk Management SolutionsTax & AccountingBlog: Answers OnInnovation @ Thomson Reuters
Directory of sites
Login
Contact
Support
Myanmar
Energy & Environment
Brexit
North Korea
Earnings
Future of Money
Breakingviews
Market News
March 16, 2018 / 11:44 AM / in an hour

BRIEF-Stemline Therapeutics Q4 Loss Per Share $0.93

Reuters Staff

1 Min Read

March 16 (Reuters) - Stemline Therapeutics Inc:

* STEMLINE THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

* Q4 LOSS PER SHARE $0.93

* Q4 EARNINGS PER SHARE VIEW $-0.70 — THOMSON REUTERS I/B/E/S

* ‍ENDED Q4 OF 2017 WITH $66.2 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

© 2018 Reuters. All Rights Reserved.